How to make a million WITHOUT buying ‘sin stocks’

Bilaal Mohamed explains how ethical investing can still be a very profitable way to build wealth.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the festive season well under way, I thought it would be a good time to contemplate whether it is possible to build a winning investment portfolio based on sound ethical principles. But then I hit my first obstacle. What does ‘ethical’ mean?

Does your mother know

Ask 10 people what ethical means and you’ll probably get 10 different answers, and kick off a heated discussion about the topic. It can be a rather emotive subject for investors too. Some would be quite happy to include oil and mining stocks in an ethical portfolio, yet others would cite their negative environmental impact and say they were therefore unethical.

So finally I decided to narrow the scope to so-called ‘sin stocks’. It’s generally accepted that ‘sin stocks’ are those belonging to sectors that include alcohol, tobacco, gambling, weapons manufacture, and other naughty things you wouldn’t want your mother to know about.

Defensives

It’s not as easy as it seems, when you consider that companies in these sectors have generally outperformed the market over the years, with many now even considered as ‘defensives’. In other words, even when the economy is struggling, people are less likely to cut back on booze and tobacco for instance, than they are on retail and housing.

What does it say about society when alcohol, tobacco, and gambling rank alongside gas, water, electricity, toothpaste, and toilet paper as everyday essentials? When times are good – people drink, smoke and gamble. When times aren’t so good, they do so even more.

A healthier alternative

Core holdings like Diageo, Imperial Brands and British American Tobacco might not be that well known to those outside the investment community. But with instantly-recognisable global brands such Guinness, Baileys, Rothmans and Lucky Strike in their portfolios, these three goliaths last year managed to amass sales in excess of £60bn, with a large chunk of the profits being distributed to their shareholders.

Is there an alternative? I think there is. Why not invest in equally defensive companies that produce inhalers, vaccines, and cancer treatments? I’m talking about London-listed pharmaceutical giants GlaxoSmithKline and AstraZeneca. Both are go-to stocks in times of economic uncertainty, and both pay healthy dividends to their loyal shareholders. You’ll probably feel better about it too.

The only way is ethics

As one of the world’s largest weapons suppliers, BAE Systems has long been a target for both campaigners and investors, with the multinational defence contractor last year pulling in almost £19bn of business from countries all around the world.

Medical technology business Smith & Nephew on the other hand has been helping the wounded since the outbreak of the First World War. The company’s advanced wound management and joint replacement systems have helped to deliver an enviable track record of revenue and earnings growth over the years, and I see the company as a worthy alternative to BAE in a ‘sinless’ portfolio.

And as more corporations realise their customers expect them to ‘do good’ (as well as making good products) they’re more likely to take an actively ethical approach to business, making it even easier to avoid sin stocks.

As you can see, it’s just as easy to build a winning portfolio with companies you’d be proud to own, as it is with more ethically-challenged stocks. So why not give it a try?

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, Diageo, and Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Investing Articles

As oil prices soar, is it time to buy Shell shares?

Christopher Ruane weighs some pros and cons of adding Shell shares to his ISA -- and explains why the oil…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

How much do you need in an ISA for £6,751 passive income a year in 2046?

Let's say an investor wanted a passive income in 20 years' time. How much cash would need be built up…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Why isn’t the IAG share price crashing?

Harvey Jones expected the IAG share price to take an absolute beating during current Middle East hostilities. So why is…

Read more »

piggy bank, searching with binoculars
Growth Shares

1 UK share I’d consider buying and 1 I’d run away from on this market dip

In light of the recent stock market dip, Jon Smith outlines the various potential outcomes for a couple of different…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

AI may look like a bubble. But what about Rolls-Royce shares?

Bubble talk has been centred on some AI stocks lately. But Christopher Ruane sees risks to Rolls-Royce shares in the…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Will the BAE Systems share price soar 13% by this time next year?

BAE Systems' share price continues to surge as the Middle East crisis worsens. Royston Wild asks if the FTSE 100…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this a once-in-a-decade chance to bag a 9.9% yield from Taylor Wimpey shares?

Taylor Wimpey shares have been hit by a volatile share price and cuts to the dividend. Harvey Jones holds the…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Way up – or way down? This FTSE 250 share could go either way

Can this FTSE 250 share turn its fortunes around? Or has its day passed? Our writer looks at both sides…

Read more »